Introduction
CYP2D6 metabolizes many clinically important drugs including antidepressants, neuroleptics, b-blockers and antiarrhythmics. 1) There is a wide interethnic variation in the frequency of the CYP2D6 genotypes. In a previous study, we reported the frequencies of CYP2D6 genotypes in a Japanese population.
2) However, some alleles have since been reported which were not included in our study.
In the present study, we focused on the -1584C W G substitution, because the subjects with -1584G were suggested to have higher CYP2D6 enzyme activity than those with -1584C.
3) The locations of the mutations in common CYP2D6 alleles are displayed in Fig. 1 according to the CYP nomenclature committee (http: W W www. imm.ki.se W CYPalleles W cyp2d6.htm), with some modiˆ-cations. Since the single nucleotide polymorphism (SNP) in -1584 seems to be mainly associated with CYP2D6*2, the committee has designated CYP2D6*2 with -1584G as CYP2D6 * 2A and CYP2D6 * 2 with -1584C as CYP2D6*41, according to Zanger et al.
3)
Recent studies have suggested that individuals with CYP2D6 * 41 have lower CYP2D6 enzymatic activity in vivo than those with CYP2D6*2A, 4) possibly as a consequence of lower expression of CYP2D6 protein.
3)
The -1584G substitution is also found in the CYP2D6*35 allele, which has a 31G to A substitution in addition to the SNPs of the CYP2D6 * 2 allele, but does not have the gene conversion mutation from CYP2D7 in intron 1 of CYP2D6. Although the allele has been identiˆed in many duplication-negative``Ultra rapid'' metabolizers, 5) the activity of recombinant CYP2D6.35 is comparable to that of the wild-type. 6) Furthermore, the -1584G is found in the CYP2D6*21 allele. However, these eŠective alleles have been classiˆed as CYP2D6*2 according to previous detection criteria. Therefore, the consideration of these alleles may result in a better understanding of the phenotype-genotype correlation.
In view of the importance of the -1584C W G substitution-related alleles in the Japanese population, we examined the frequencies of CYP2D6*41 and *35, possibly included in CYP2D6 * 2, * 21 and other alleles in the present study. 
Methods
All subjects in the present study were healthy males who had enrolled for several clinical trials. We regenotyped 206 subjects whose data had previously been reported.
2) An additional 79 subjects were newly included, and consequently a total of 285 subjects were examined for the CYP2D6 genotype. This study was approved by the ethic committees of Osaka University. Written informed consent for genetic analysis was obtained from all subjects. Genomic DNA was isolated from peripheral lymphocytes from each subject.
In our previous study, each CYP2D6 genotype was deˆned from the results of PCR-RFLP methods for 100C W T, 1846G W A, 2850C W T and 4180G W C 2) and from the results of XbaI and EcoRI-RFLP methods or the long-PCR method for the CYP2D6*5 allele. 7, 8) A PCR-RFLP method for the -1584C to G substitution was developed for it's direct detection. A mismatch PCR-RFLP assay was based on a recognition site for the restriction enzyme SmaI by utilizing an oligonucleotide mismatch primer (CYP2D6*41 Mut.R; 5?-TTG TAT TTT TTG TAG AGC CC -3?; the letter with the underline is the mismatch nucleotide). This antisense primer introduces a SmaI recognition site by extension when a cytosine is present at theˆrst base. In contrast, in the present of a guanine no recognition site for SmaI is introduced. The PCR reaction was carried out in a 25-microl reaction volume containing 1.5 mM MgCl2, 10 mM Tris W HCl (pH 8.3), 0.2 mM of each dNTP, 10 pmol of each primer (CYP2D6*41F; 5?-TTC AAG ACC AGC CTG GAC AAC -3? and CYP2D6*41Mut.R), 30 ng genomic DNA and 1U AmpliTaqGold TM DNA polymerase (Applied Biosystems). An initial denaturation step at 959 C for 10 min was followed by 35 cycles of 959 C for 30 sec, 609 C for 1 min and 729 C for 30 sec, and aˆnal elongation step of 729 C for 5 min. PCR products were then digested with SmaI and separated on 4z agarose gel. Product from the -1584C allele was not cut and remained 53 bp in length, while the -1584G allele was cut into 32 and 21 bp.
The 31G W A substitution was detected toˆnd the CYP2D6 * 35 allele according to Lovlie et al. 5) In brief, a 341-bp fragment covering the SNP was ampliˆed by a set of primers (CYP-511; 5?-AGG TTC ACT CAC AGC AGA GGG-3? and CYP-518; 5?-CCT GGT CGA AGC AGT ATG GTG-3?), then digested with NlaIII. The wildtype (31G) was cut into 305 and 36 bp fragments, while the mutant (31A) allele generated 193, 112 and 36 bp fragments. The PCR reaction product was puriˆed and directly sequenced by DNA sequencer ABI 310 using dye-terminater chemistry to conˆrm the nucleotide substitution and search for other related substitutions. Then, to determine the haplotype, the fragment was cloned using the TOPO TA cloning kit (Invitrogen) according to the manufacturer's instructions. Additionally, after genotyping, some clones with insertions were randomly selected and directly sequenced.
The presence of the CYP2D6*21 allele was determined by an allele speciˆc PCR method using genotyping kit``-SNP Typing Kit-Cytochrome P450 2D6*21 (2573C insert)'' (TOYOBO, Japan) according to the manufacturer's instructions.
Results
The -1584G alleles were detected in the subjects previously determined as having the CYP2D6 * 2 genotype. The frequency of -1584G substitution in the Japanese population was estimated to be 0.114 and CYP2D6*41 allelic frequency 0.026 (Table 1) .
Interestingly, there were four unusual subjects among all of the subjects with the -1584G allele. One subject was heterozygous for -1584G and had substitutions classiˆed as CYP2D6*1 W *10. Two subjects were also heterozygous for -1584G although both had CYP2D6*1 W *14. The last was homozygous for -1584G in spite of CYP2D6 * 2 W * 14 carrier according to the previous classiˆcation.
The insertion of cytosine at 2573 was detected in three 115 The CYP2D6 * 41 and * 35 alleles in Japanese subjects, which indicates that they had the CYP2D6*21 allele. Consistent with the allelic information on CYP2D6 * 21, the heterozygous for -1584G was detected from all three. Therefore, one subject was genotyped as CYP2D6 * 10 W * 21 and the other two as CYP2D6 * 1 W *21. As a result, the frequency of CYP2D6*21 allele was estimated to be 0.005 in the present study.
One subject was found to be heterozygous for the 31G to A substitution with CYP2D6*1 W *10 according to the previous classiˆcation. In the same subject, we also detected an allele carrying 100T and 31A by subcloning analysis. However, the allelic information on CYP2D6 * 35 showed no link between the 31A and the 100T. Therefore, we did not consider the subject to be a CYP2D6*35 carrier, but provisionally as a CYP2D6*1 W *10 carrier, which may be a new type of allele related to CYP2D6*10 with 31A.
Discussion
In the past, we have classiˆed CYP2D6*2 as the wild-type enzymic status according to the phenotype test. However, we have, on occasion, encountered subjects with a lower enzyme activity than that expected of the CYP2D6*2 genotype. In the Caucasian population, subjects with -1584G substitutions including CYP2D6*2 have been reported to achieve higher CYP2D6 activity in vivo than those with -1584C, possibly as a consequence of greater expression of the CYP2D6 protein. 3, 4) In addition, irrespective of the genotype, individuals with -1584C W C expressed less CYP2D6 protein than individuals with at least one -1584G allele.
3) There has been no study concerning the -1584C W G substitution in the Japanese population.
In the present study, we conˆrmed that the -1584G allele was also detected in the Japanese population although its frequency is lower than in other ethnic groups (Table 1) . Therefore, our results did not disprove the presence of a possible inconsistency between the phenotype and genotype of CYP2D6 found in several previous studies for Japanese, regarding the eŠect of this SNP on the activity of CYP2D6.
We also examined the 31G to A substitution for presence of CYP2D6 * 35 as a related-allele with the -1584C W G substitution. In this study, the heterozygous for 31A was found in only one subject with CYP2D6 * 1 W *10. We subcloned the sample and detected the *10 allele with the 31A mutation as a minor novel allele. This was not regarded as CYP2D6 * 35. Although the 31G W A substitution is not likely to in‰uence CYP2D6 enzyme activity and protein expression level in vitro, 6) the CYP2D6*35 allele is found in many ultra rapid metabolizers. 5, 9) The presentˆndings suggest that CYP2D6 * 35 allele frequency in the Japanese population is very low, compared with some other ethnic populations, which is consistent with the fact that the ultra rapid metabolizers are rare in Japanese 2) and occur in less than about 10z of Caucasians.
The result from four unusual subjects suggests that the -1584G substitution might be associated with CYP2D6*14 and possibly CYP2D6*1 or *10 in addition to CYP2D6*2, *21 and *35. Zanger et al. also mentioned that one subject with CYP2D6*1 W *1 possessing -1584G was detected in their study, 3) supporting the present result. On the other hand, Gaedigk et al. suggested that CYP2D6 poor metabolizers (PMs) can be detected by the selection of -1584G carriers, as -1584G is exclusively linked to functional allelic variants. 9) Their study seems to be of value for the simple clinical use of the SNP information. However, the connection between the *14 allele and the -1584G substitution was found in the present study in addition to *21. Since CYP2D6*14 is a null-allele characteristic to the Japanese population, these connections may limit the genotyping strategy to Japanese.
In conclusion, we examined the distribution of -1584C W G substitutions in the Japanese population mainly associated with CYP2D6*2, and found the frequency showed interethnic variation. Since the -1584C W G substitution-related alleles potentially eŠect CYP2D6 enzyme activity, these alleles should be consi-dered in CYP2D6 genotyping. The present study found that the -1584C W G substitution has a potential link to other alleles, and further studies on the related alleles in various ethnic populations are necessary.
